Goldman Sachs Maintains Sell on Intellia Therapeutics, Raises Price Target to $9

Benzinga Newsdesk www.benzinga.com Positive 82.5%

Neg 0% Neu 0% Pos 82.5%

Goldman Sachs analyst Salveen Richter maintains Intellia Therapeutics (NASDAQ:NTLA) with a Sell and raises the price target from $8 to $9.